BioStock Studio: Abliva on the 200 MSEK financing round

Yesterday, biotech Abliva, whose focus is on primary mitochondrial diseases, announced that it has decided on a 200 million SEK financing round. The funding consists of a directed share issue of approximately 150 million SEK and a rights issue of approximately 50 million SEK. Abliva’s CEO Ellen Donnelly told BioStock about raising capital under challenging market conditions and how the proceeds will be used.

See the interview with Ellen Donnelly, in English, at biostock.se:

https://www.biostock.se/en/2022/06/abliva-on-the-200-msek-financing-round/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se